Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions

Breast Cancer

Interventions

DRUG

Dalpiciclib

150 mg qd

DRUG

Fulvestrant

500mg d1, 15, 29, and then q4w

DRUG

Pertuzumab

840mg q3w, and then 420 mg q3w

DRUG

Trastuzumab

8 mg/kg q3w, and then 6 mg/kg q3w

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER